Finding new drugs to fight tuberculosis
Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling
This study is looking for new ways to fight tough cases of tuberculosis by testing different compounds to see how they affect the bacteria, which could help develop better treatments for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10974471 on NIH RePORTER |
What this research studies
This research aims to discover new antimicrobial agents to combat multi-drug resistant tuberculosis by using advanced techniques like CRISPR and high-throughput metabolic profiling. The approach involves analyzing the metabolic effects of various compounds on the tuberculosis bacteria, allowing researchers to understand how these drugs work at a deeper level. By examining the interactions between genetic changes and drug effects, the study seeks to identify the mechanisms of action for a large library of potential anti-TB drugs. This could lead to innovative strategies for treating tuberculosis more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, especially those with multi-drug resistant strains.
Not a fit: Patients who do not have tuberculosis or those with non-infectious conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and effective treatments for tuberculosis, particularly for strains resistant to current medications.
How similar studies have performed: Other research has shown promise in using high-throughput methods and CRISPR technology to identify new drug candidates, indicating that this approach has potential for success.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Berney, Michael — Albert Einstein College of Medicine
- Study coordinator: Berney, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.